Form 4: NMSIC Co-Investment Fund Sells 200,000 Shares of Exagen Inc.

NMSIC Co-Investment Fund, a 10% owner of Exagen Inc., sold 200,000 shares of common stock at a price of $3.3002 per share.

Summary

• NMSIC Co-Investment Fund, L.P., a significant shareholder of Exagen Inc., has sold 200,000 shares of the company's common stock.
• The transaction occurred on November 20, 2024, with the shares being sold at a price of $3.3002 each.
• Following the sale, NMSIC Co-Investment Fund, L.P. still indirectly holds 2,108,958 shares of Exagen Inc.
• Sun Mountain Capital Partners LLC, as the general partner of NMSIC, is also considered to have indirect beneficial ownership of these shares.
• Brian Birk, Sally Coming, and Lee Rand, the controlling members of Sun Mountain, may also be deemed to share beneficial ownership, though they disclaim it.

Sentiment

Score: 4

Explanation: The sale of shares by a major shareholder is generally viewed as a negative signal, although the fund still retains a significant stake. The sentiment is therefore slightly negative.

Negatives

• A significant shareholder, NMSIC Co-Investment Fund, L.P., has reduced its stake in Exagen Inc. by selling 200,000 shares, which could be perceived negatively by the market.

Risks

• The sale of a large block of shares by a major shareholder could potentially put downward pressure on the stock price.
• The market may interpret this sale as a lack of confidence in the company's future prospects by a major investor.

Management Comments

• Brian Birk and Lee Rand, as managing partners of Sun Mountain Capital Partners LLC, signed the form on behalf of NMSIC Co-Investment Fund, L.P.

Industry Context

This transaction is a routine disclosure of insider trading activity and does not necessarily indicate a broader trend in the diagnostics industry. However, large sales by major shareholders are often closely watched by the market.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders in publicly traded companies.
• The sale of 200,000 shares is a significant transaction, but not unusual for a fund of this size.
• Comparable transactions would include similar filings by other major shareholders in publicly traded companies.

Stakeholder Impact

• Shareholders may react negatively to the sale of shares by a major investor, potentially leading to a decrease in the stock price.
• Employees may be concerned about the implications of a major shareholder reducing their stake.

Key Dates

Keywords

Exagen Inc, NMSIC Co-Investment Fund, Sun Mountain Capital Partners, share sale, insider trading, beneficial ownership, stock transaction